Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice.
暂无分享,去创建一个
P. Vollenweider | R. Burcelin | B. Thorens | P. Nicod | O. Hugli | U. Scherrer | M. Egli | S. Cook
[1] U. Scherrer,et al. Insulin resistance, a new target for nitric oxide‐delivery drugs , 2002, Fundamental & clinical pharmacology.
[2] M. Matsuhisa,et al. Association of -786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance , 2002, Diabetologia.
[3] P. Vollenweider,et al. Insulin Resistance, Hyperlipidemia, and Hypertension in Mice Lacking Endothelial Nitric Oxide Synthase , 2001, Circulation.
[4] C. Sartori,et al. Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation. , 1999, Journal of hypertension.
[5] H. Itoh,et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. , 1998, Hypertension.
[6] I. Godsland,et al. Hyperleptinemia as a Component of a Metabolic Syndrome of Cardiovascular Risk , 1998 .
[7] M. Taskinen,et al. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM , 1996, Diabetologia.
[8] P. Vollenweider,et al. Nitric oxide release accounts for insulin's vascular effects in humans. , 1994, The Journal of clinical investigation.
[9] A. Quyyumi,et al. Role of Endothelium‐Derived Nitric Oxide in the Abnormal Endothelium‐Dependent Vascular Relaxation of Patients With Essential Hypertension , 1993, Circulation.
[10] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[11] H. Halkin,et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. , 1985, The Journal of clinical investigation.
[12] R A Shaffer,et al. State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. , 1999, Hypertension.